First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
Eduardo Díaz‐Rubio(Hospital Clínico San Carlos), Enrique Aranda(Instituto Maimónides de Investigación Biomédica de Córdoba), Amelia López-Ladrón(Hospital Universitario de Valme), A. Arriví(Hospital Son Llatzer), Lacasta, Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), María José Safont(Hospital General Universitario De Valencia), Marta Llanos(Hospital Universitario de Canarias), Benavides, P. Escudero(Hospital Clínico Universitario Lozano Blesa), Ferrán Losa, Albert Abad, Carlos Fernández-Martos(Fundación Instituto Valenciano de Oncología), Encarnación González‐Flores(Hospital Universitario Virgen de las Nieves), Manuel Gallén(Hospital Del Mar), Javier Sastre(Hospital Clínico San Carlos), Fernando Rivera(Marqués de Valdecilla University Hospital), Antonio Antón(Hospital Universitario Miguel Servet), Andrés Cervantes(INCLIVA Health Research Institute), Duenas Duenas, Eugenio Marcuello(Hospital de Sant Pau), Tabernero, M Jose, Purificación Martínez de Prado(Hospital de Basurto), Adelaida, Manuel Valladares(American Society of Clinical Oncology), Auxiliadora Gómez‐España(Hospital Universitario Reina Sofía)
Unknown
April 23, 2012
Cited by 25
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k